{"transactions":[{"id":740162,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:57:52.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073615","document":"tm2617880-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465926073615/tm2617880-8_4seq1.xml","form_type":"4"}},{"id":997952,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2025-11-17T17:48:26.000Z","date":"2025-11-16","kind":"grant","planned":false,"acquired":true,"shares":311100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027."}],"balance_after":311100,"derivative":{"exercise_price":1.23,"expiration_date":"2035-11-16","underlying":"Common Stock","underlying_shares":311100},"source":{"system":"sec-edgar","filing":"0001628280-25-052715","document":"wk-form4_1763419703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000162828025052715/wk-form4_1763419703.xml","form_type":"4"}},{"id":1060419,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2025-08-20T19:29:04.000Z","date":"2025-08-20","kind":"sale","planned":false,"acquired":false,"shares":591685,"price":1.58,"value":934862.3,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.53 to $1.69. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-081008","document":"tm2524042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465925081008/tm2524042-1_4seq1.xml","form_type":"4"}},{"id":1060418,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2025-08-20T19:29:04.000Z","date":"2025-08-19","kind":"sale","planned":false,"acquired":false,"shares":1100000,"price":1.63,"value":1793000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.57 to $1.76. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":591685,"source":{"system":"sec-edgar","filing":"0001104659-25-081008","document":"tm2524042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465925081008/tm2524042-1_4seq1.xml","form_type":"4"}},{"id":1060417,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2025-08-20T19:29:04.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":549360,"price":1.83,"value":1005328.8,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.79 to $1.92. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1691685,"source":{"system":"sec-edgar","filing":"0001104659-25-081008","document":"tm2524042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465925081008/tm2524042-1_4seq1.xml","form_type":"4"}},{"id":1109972,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:31:44.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first 25% of the option becomes exercisable on  June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":0,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000113","document":"wk-form4_1750105897.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838225000113/wk-form4_1750105897.xml","form_type":"4"}},{"id":1296533,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T16:34:25.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":1130311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":1130311,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":1130311},"source":{"system":"sec-edgar","filing":"0001818382-25-000017","document":"wk-form4_1737668058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838225000017/wk-form4_1737668058.xml","form_type":"4"}},{"id":1324317,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2024-12-20T17:09:42.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant."}],"balance_after":2625,"derivative":{"exercise_price":10.28,"exercise_date":"2024-12-19","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-24-000231","document":"wk-form4_1734732576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000231/wk-form4_1734732576.xml","form_type":"4"}},{"id":1355932,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-21T07:31:17.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":1797,"price":4.44,"value":7978.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":243851,"source":{"system":"sec-edgar","filing":"0001818382-24-000214","document":"wk-form4_1732192270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000214/wk-form4_1732192270.xml","form_type":"4"}},{"id":1357428,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-20T19:06:35.000Z","date":"2024-11-20","kind":"sale","planned":false,"acquired":false,"shares":261369,"price":4.4,"value":1150023.6,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1730884,"source":{"system":"sec-edgar","filing":"0001818382-24-000208","document":"wk-form4_1732147588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000208/wk-form4_1732147588.xml","form_type":"4"}},{"id":1357427,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-20T19:06:35.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":427459,"price":4.34,"value":1855172.06,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1992253,"source":{"system":"sec-edgar","filing":"0001818382-24-000208","document":"wk-form4_1732147588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000208/wk-form4_1732147588.xml","form_type":"4"}},{"id":1357426,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-20T19:06:35.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":811172,"price":4.44,"value":3601603.68,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2419712,"source":{"system":"sec-edgar","filing":"0001818382-24-000208","document":"wk-form4_1732147588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000208/wk-form4_1732147588.xml","form_type":"4"}},{"id":1409885,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-09-11T17:50:36.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":288674,"price":5.23,"value":1509765.02,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3230884,"source":{"system":"sec-edgar","filing":"0001818382-24-000184","document":"wk-form4_1726091430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000184/wk-form4_1726091430.xml","form_type":"4"}},{"id":1409884,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-09-11T17:50:36.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":157704,"price":5.42,"value":854755.68,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3519558,"source":{"system":"sec-edgar","filing":"0001818382-24-000184","document":"wk-form4_1726091430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000184/wk-form4_1726091430.xml","form_type":"4"}},{"id":1417886,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-09-03T16:23:53.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":1222,"price":6.545,"value":7997.99,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase."}],"balance_after":242054,"source":{"system":"sec-edgar","filing":"0001818382-24-000177","document":"wk-form4_1725395025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000177/wk-form4_1725395025.xml","form_type":"4"}},{"id":1420040,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-08-29T18:48:06.000Z","date":"2024-08-29","kind":"sale","planned":false,"acquired":false,"shares":352112,"price":6.35,"value":2235911.2,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3677262,"source":{"system":"sec-edgar","filing":"0001818382-24-000166","document":"wk-form4_1724971594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000166/wk-form4_1724971594.xml","form_type":"4"}},{"id":1420039,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-08-29T18:48:06.000Z","date":"2024-08-28","kind":"sale","planned":false,"acquired":false,"shares":277090,"price":6.47,"value":1792772.3,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4029374,"source":{"system":"sec-edgar","filing":"0001818382-24-000166","document":"wk-form4_1724971594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000166/wk-form4_1724971594.xml","form_type":"4"}},{"id":1420038,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-08-29T18:48:06.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":252676,"price":6.71,"value":1695455.96,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4306464,"source":{"system":"sec-edgar","filing":"0001818382-24-000166","document":"wk-form4_1724971594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000166/wk-form4_1724971594.xml","form_type":"4"}},{"id":1477497,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T16:12:09.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000138","document":"wk-form4_1718655122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000138/wk-form4_1718655122.xml","form_type":"4"}},{"id":1480911,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-13T16:48:33.000Z","date":"2024-06-12","kind":"sale","planned":false,"acquired":false,"shares":271518,"price":7.3,"value":1982081.4,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4559140,"source":{"system":"sec-edgar","filing":"0001818382-24-000101","document":"wk-form4_1718311705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000101/wk-form4_1718311705.xml","form_type":"4"}},{"id":1480910,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-13T16:48:33.000Z","date":"2024-06-11","kind":"sale","planned":false,"acquired":false,"shares":76630,"price":7.02,"value":537942.6,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4830658,"source":{"system":"sec-edgar","filing":"0001818382-24-000101","document":"wk-form4_1718311705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000101/wk-form4_1718311705.xml","form_type":"4"}},{"id":1480909,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-13T16:48:33.000Z","date":"2024-06-11","kind":"sale","planned":false,"acquired":false,"shares":282000,"price":7.0922,"value":2000000.4,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold in a private transaction to a trust controlled by family members of the Reporting Person. Said family members do not share the same household as the Reporting Person."}],"balance_after":4907288,"source":{"system":"sec-edgar","filing":"0001818382-24-000101","document":"wk-form4_1718311705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000101/wk-form4_1718311705.xml","form_type":"4"}},{"id":1492792,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-04T19:05:25.000Z","date":"2024-06-04","kind":"purchase","planned":false,"acquired":true,"shares":2362,"price":6.35,"value":14998.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 93,213 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $7,015.79, representing the full amount of profit realized in connection with this purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.3497 to $6.3499. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":240832,"source":{"system":"sec-edgar","filing":"0001818382-24-000087","document":"wk-form4_1717542316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000087/wk-form4_1717542316.xml","form_type":"4"}},{"id":1492791,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-04T18:57:57.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":1852,"price":7.28,"value":13482.56,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5189288,"source":{"system":"sec-edgar","filing":"0001818382-24-000084","document":"wk-form4_1717541869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000084/wk-form4_1717541869.xml","form_type":"4"}},{"id":1492790,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-04T18:57:57.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":190214,"price":7.42,"value":1411387.88,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5191140,"source":{"system":"sec-edgar","filing":"0001818382-24-000084","document":"wk-form4_1717541869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000084/wk-form4_1717541869.xml","form_type":"4"}},{"id":1492789,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-04T18:57:57.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":93213,"price":8.93,"value":832392.09,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"shares","element":"transactionShares","label":"F3","text":"A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Dr. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5381354,"source":{"system":"sec-edgar","filing":"0001818382-24-000084","document":"wk-form4_1717541869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000084/wk-form4_1717541869.xml","form_type":"4"}},{"id":1492788,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-04T18:57:57.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":716573,"price":7.78,"value":5574937.94,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5474567,"source":{"system":"sec-edgar","filing":"0001818382-24-000084","document":"wk-form4_1717541869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000084/wk-form4_1717541869.xml","form_type":"4"}},{"id":1495366,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-06-03T16:31:36.000Z","date":"2024-06-03","kind":"purchase","planned":false,"acquired":true,"shares":2050,"price":7.37,"value":15108.5,"ownership":{"direct":true},"balance_after":238470,"source":{"system":"sec-edgar","filing":"0001818382-24-000076","document":"wk-form4_1717446687.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000076/wk-form4_1717446687.xml","form_type":"4"}},{"id":1714567,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2023-12-12T16:09:17.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant."}],"balance_after":2100,"derivative":{"exercise_price":10.28,"exercise_date":"2023-12-11","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-23-000191","document":"wk-form4_1702415348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000191/wk-form4_1702415348.xml","form_type":"4"}},{"id":1714566,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2023-12-12T16:09:17.000Z","date":"2023-12-08","kind":"grant","planned":false,"acquired":true,"shares":803000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027."}],"balance_after":803000,"derivative":{"exercise_price":2.8,"expiration_date":"2033-12-08","underlying":"Common Stock","underlying_shares":803000},"source":{"system":"sec-edgar","filing":"0001818382-23-000191","document":"wk-form4_1702415348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000191/wk-form4_1702415348.xml","form_type":"4"}},{"id":1762768,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2023-10-10T16:08:08.000Z","date":"2023-10-10","kind":"exercise","planned":false,"acquired":false,"shares":114420,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48176,"derivative":{"exercise_price":1.19,"exercise_date":"2016-11-22","expiration_date":"2023-11-23","underlying":"Common Stock","underlying_shares":114420},"source":{"system":"sec-edgar","filing":"0001818382-23-000153","document":"wk-form4_1696968477.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000153/wk-form4_1696968477.xml","form_type":"4"}},{"id":1762767,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-10-10T16:08:08.000Z","date":"2023-10-10","kind":"exercise","planned":false,"acquired":true,"shares":114420,"price":1.19,"value":136159.8,"ownership":{"direct":true},"balance_after":1384660,"source":{"system":"sec-edgar","filing":"0001818382-23-000153","document":"wk-form4_1696968477.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000153/wk-form4_1696968477.xml","form_type":"4"}},{"id":1780287,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-09-15T16:06:18.000Z","date":"2023-09-14","kind":"sale","planned":false,"acquired":false,"shares":2000000,"price":2.78,"value":5560000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."}],"balance_after":6191140,"source":{"system":"sec-edgar","filing":"0001818382-23-000130","document":"wf-form4_169480836158057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000130/wf-form4_169480836158057.xml","form_type":"4"}},{"id":1800931,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-08-21T18:07:49.000Z","date":"2023-08-21","kind":"sale","planned":false,"acquired":false,"shares":602443,"price":3.39,"value":2042281.77,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8191140,"source":{"system":"sec-edgar","filing":"0001818382-23-000121","document":"wf-form4_169265565726867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000121/wf-form4_169265565726867.xml","form_type":"4"}},{"id":1800930,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-08-21T18:07:49.000Z","date":"2023-08-18","kind":"sale","planned":false,"acquired":false,"shares":626979,"price":3.57,"value":2238315.03,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8793583,"source":{"system":"sec-edgar","filing":"0001818382-23-000121","document":"wf-form4_169265565726867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000121/wf-form4_169265565726867.xml","form_type":"4"}},{"id":1800929,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-08-21T18:07:49.000Z","date":"2023-08-17","kind":"sale","planned":false,"acquired":false,"shares":570174,"price":3.68,"value":2098240.32,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9420562,"source":{"system":"sec-edgar","filing":"0001818382-23-000121","document":"wf-form4_169265565726867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000121/wf-form4_169265565726867.xml","form_type":"4"}},{"id":1852679,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2023-06-16T16:09:37.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027."}],"balance_after":8500,"derivative":{"exercise_price":3.35,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001818382-23-000084","document":"wf-form4_168694616392845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000084/wf-form4_168694616392845.xml","form_type":"4"}},{"id":1852678,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-06-16T16:04:55.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":3.1175,"value":1558750.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."}],"balance_after":9990736,"source":{"system":"sec-edgar","filing":"0001818382-23-000083","document":"wf-form4_168694588567524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000083/wf-form4_168694588567524.xml","form_type":"4"}},{"id":1854675,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-06-15T16:21:19.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":4875000,"price":2.6,"value":12675000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."}],"balance_after":10490736,"source":{"system":"sec-edgar","filing":"0001818382-23-000049","document":"wf-form4_168686046417140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000049/wf-form4_168686046417140.xml","form_type":"4"}},{"id":1876771,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-05-26T17:05:10.000Z","date":"2023-05-25","kind":"sale","planned":false,"acquired":false,"shares":2625000,"price":2.75,"value":7218750.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."}],"balance_after":15365736,"source":{"system":"sec-edgar","filing":"0001104659-23-065546","document":"tm2317123-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465923065546/tm2317123-9_4seq1.xml","form_type":"4"}},{"id":1980043,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2023-03-02T16:04:04.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":162596,"derivative":{"exercise_price":1.19,"exercise_date":"2016-11-22","expiration_date":"2023-11-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001818382-23-000003","document":"wf-form4_167779102542302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000003/wf-form4_167779102542302.xml","form_type":"4"}},{"id":1980042,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2023-03-02T16:04:04.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":100000,"price":1.19,"value":119000.0,"ownership":{"direct":true},"balance_after":1270240,"source":{"system":"sec-edgar","filing":"0001818382-23-000003","document":"wf-form4_167779102542302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838223000003/wf-form4_167779102542302.xml","form_type":"4"}},{"id":2082038,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-12-19T20:27:32.000Z","date":"2022-12-15","kind":"purchase","acquired":true,"shares":10000,"price":2.54,"value":25400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1170240,"source":{"system":"sec-edgar","filing":"0001818382-22-000223","document":"wf-form4_167149963704147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000223/wf-form4_167149963704147.xml","form_type":"4"}},{"id":2082037,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-12-19T20:23:23.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":239538,"price":2.53,"value":606031.14,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17990736,"source":{"system":"sec-edgar","filing":"0001818382-22-000221","document":"wf-form4_167149938921327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000221/wf-form4_167149938921327.xml","form_type":"4"}},{"id":2085302,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-12-15T19:51:58.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":93426,"price":2.63,"value":245710.38,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18230274,"source":{"system":"sec-edgar","filing":"0001818382-22-000211","document":"wf-form4_167115188797248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000211/wf-form4_167115188797248.xml","form_type":"4"}},{"id":2085301,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-12-15T19:51:58.000Z","date":"2022-12-14","kind":"sale","acquired":false,"shares":276304,"price":2.76,"value":762599.04,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.75 to $2.87. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18323700,"source":{"system":"sec-edgar","filing":"0001818382-22-000211","document":"wf-form4_167115188797248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000211/wf-form4_167115188797248.xml","form_type":"4"}},{"id":2085300,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-12-15T19:51:58.000Z","date":"2022-12-13","kind":"sale","acquired":false,"shares":330000,"price":2.84,"value":937200.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18600004,"source":{"system":"sec-edgar","filing":"0001818382-22-000211","document":"wf-form4_167115188797248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000211/wf-form4_167115188797248.xml","form_type":"4"}},{"id":2089939,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-12T16:11:17.000Z","date":"2022-12-08","kind":"grant","acquired":true,"shares":444500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026."}],"balance_after":444500,"derivative":{"exercise_price":3.07,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":444500},"source":{"system":"sec-edgar","filing":"0001818382-22-000197","document":"wf-form4_167087945823074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000197/wf-form4_167087945823074.xml","form_type":"4"}},{"id":2156025,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-09-19T16:48:07.000Z","date":"2022-09-15","kind":"purchase","acquired":true,"shares":2000,"price":4.14,"value":8280.0,"ownership":{"direct":true},"balance_after":1160240,"source":{"system":"sec-edgar","filing":"0001818382-22-000167","document":"wf-form4_166362046815607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000167/wf-form4_166362046815607.xml","form_type":"4"}},{"id":2156024,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-09-19T16:36:28.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":1522500,"price":4,"value":6090000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made by an entity controlled by the spouse of Laura Niklason, the Reporting Person. This sale was done as a block trade to an existing investor of Humacyte, Inc. Laura Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Laura Niklason were sold in this transaction."}],"balance_after":18930004,"source":{"system":"sec-edgar","filing":"0001818382-22-000161","document":"wf-form4_166361976999359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000161/wf-form4_166361976999359.xml","form_type":"4"}},{"id":2234413,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2022-06-13T16:21:02.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026."}],"balance_after":8500,"derivative":{"exercise_price":4.34,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001818382-22-000089","document":"wf-form4_165515163845765.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000089/wf-form4_165515163845765.xml","form_type":"4"}},{"id":2256923,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2022-05-25T10:21:10.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":10000,"price":4.83,"value":48300.0,"ownership":{"direct":true},"balance_after":1158240,"source":{"system":"sec-edgar","filing":"0001818382-22-000050","document":"wf-form4_165348845280981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838222000050/wf-form4_165348845280981.xml","form_type":"4"}},{"id":2470178,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-12-16T19:46:50.000Z","date":"2021-12-16","kind":"sale","acquired":false,"shares":75000,"price":9,"value":675000.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.79 to $9.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":510161,"source":{"system":"sec-edgar","filing":"0001104659-21-150678","document":"tm2135715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921150678/tm2135715-1_4seq1.xml","form_type":"4"}},{"id":2470177,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-12-16T19:46:50.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":125000,"price":8.885,"value":1110625.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.68 to $9.43. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":585161,"source":{"system":"sec-edgar","filing":"0001104659-21-150678","document":"tm2135715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921150678/tm2135715-1_4seq1.xml","form_type":"4"}},{"id":2470176,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-12-16T19:46:50.000Z","date":"2021-12-14","kind":"sale","acquired":false,"shares":76306,"price":9.325,"value":711553.45,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.825 to $9.49. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":710161,"source":{"system":"sec-edgar","filing":"0001104659-21-150678","document":"tm2135715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921150678/tm2135715-1_4seq1.xml","form_type":"4"}},{"id":2470175,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-12-16T19:46:50.000Z","date":"2021-12-14","kind":"sale","acquired":false,"shares":23694,"price":9.798,"value":232153.812,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Ayabudge LLC of 1,522,500 shares of the Issuer's common stock on August 26, 2021, at a price per share of $10.00. The Reporting Person's spouse has paid the Issuer $71.21, representing the full amount of profit realized in connection with this sale."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.50 to $10.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":786467,"source":{"system":"sec-edgar","filing":"0001104659-21-150678","document":"tm2135715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921150678/tm2135715-1_4seq1.xml","form_type":"4"}},{"id":2541819,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-10-15T15:39:02.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025."}],"balance_after":8500,"derivative":{"exercise_price":10.03,"expiration_date":"2031-10-13","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001104659-21-126714","document":"tm2130120-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921126714/tm2130120-5_4seq1.xml","form_type":"4"}},{"id":2588586,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":17068,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":17068,"derivative":{"exercise_price":6.54,"expiration_date":"2028-04-12","underlying":"Common Stock","underlying_shares":17068},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588585,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":13129,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":13129,"derivative":{"exercise_price":2.56,"expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":13129},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588584,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":1575,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant."}],"balance_after":1575,"derivative":{"exercise_price":10.28,"exercise_date":"2021-12-14","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":1575},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588583,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":1312984,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the option will vest on each of the three anniversaries after November 9, 2020."}],"balance_after":1312984,"derivative":{"exercise_price":10.28,"exercise_date":"2021-11-09","expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":1312984},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588582,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":131298,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":131298,"derivative":{"exercise_price":6.54,"expiration_date":"2028-04-12","underlying":"Common Stock","underlying_shares":131298},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588581,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":262596,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":262596,"derivative":{"exercise_price":3.44,"expiration_date":"2026-09-14","underlying":"Common Stock","underlying_shares":262596},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588580,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":157558,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":157558,"derivative":{"exercise_price":2.56,"expiration_date":"2026-03-09","underlying":"Common Stock","underlying_shares":157558},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588579,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":13129,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":13129,"derivative":{"exercise_price":2.56,"expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":13129},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588578,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":262596,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options are fully vested and exercisable."}],"balance_after":262596,"derivative":{"exercise_price":1.19,"expiration_date":"2023-11-22","underlying":"Common Stock","underlying_shares":262596},"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588577,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"purchase","acquired":true,"shares":1522500,"price":10,"value":15225000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"balance_after":20452504,"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588576,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":18930004,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 26, 2021 , Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc."}],"balance_after":18930004,"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}},{"id":2588575,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2021-08-27T16:15:32.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":1148240,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 26, 2021 , Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc."}],"balance_after":1148240,"source":{"system":"sec-edgar","filing":"0001104659-21-110547","document":"tm2125954-26_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465921110547/tm2125954-26_4seq1.xml","form_type":"4"}}]}